Abstract
Background/ObjectiveFKB327 is a biosimilar of the antitumour necrosis factor adalimumab reference product (RP). A randomised, double-blind (DB) phase 3 study compared the efficacy of FKB327 with the RP in patients...
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have